Over the past year, multiple phase 2 trials have shown promising results for DMT and 5-MeO-DMT derived compounds for mental illness including anxiety and depression. Ongoing studies are also looking into potential anti-addictive properties that could be used therapeutically in alcoholism or other addiction disorders. The question resolves yes if there are any phase 3 clinical trials published by January 1st 2026 showing positive results for DMT or 5-MeO-DMT in the treatment of any mental illness or addiction. The studied drugs may be patented salts or slight variations of the original psychedelic compounds, but must still have a psychedelic effect in order to count. The question resolves no if there are no published phase 3 clinical trials by the deadline, or if the only published phase 3 trials have significant safety concerns. If results are mixed, I will make the best possible determination at the time.